R59- Read some of the prospectus
Sheesh, what a lot to read ! Anyway, saw that they do 88% of their sales in North America, so yes, that would make sense to have sales centers in the US. Re, I somehow missed this one this week, but I like it. I mean $.45 for the qtr, and their revenue and earnings growth has been impressive. They have a strong balance sheet also. A medical device company in the US could fetch a 30-40 PE going forward, and they wouldn't be growing nearly as fast. So if we can assume to be able to annulize the June qtr, they are selling for an 11 PE going forward. Unless the fact that are headquarted in Israel knocks the valuation down substantially, sounds very cheap to me even at $20.
